Clinical studies have found that patients with NRAS-mutant melanoma tend to be older (> 55 years), have longer UV exposure, have thicker tumors at the time of diagnosis, and have a higher mitotic rate than patients with BRAF-mutant melanoma [31].Mutations in the KIT oncogene account for 3% of all melanomas. The gene discussed is BRAF; the disease is melanoma.